D
Moderna, Inc. MRNA
$28.54 $0.722.59% NASDAQ
Recommendation
Prev Close
$27.82
Volume
7,729,944
Avg Vol (90D)
10,749,313
Market Cap
$10.76B
Dividend & Yield
--
52-Week Range
$23.15 - $170.47
P/E (TTM)
--
EPS (TTM)
-$9.30
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
MarketBeat Week in Review – 03/10 - 03/14
3/15/2025 - MarketBeat
Moderna, Inc. (MRNA): Among the Worst Performing Stocks in S&P 500 So Far in 2025
4/30/2025 - Insider Monkey
Moderna (MRNA) Faces Skepticism Ahead of Earnings Report
4/30/2025 - GuruFocus
Moderna Q1 Earnings Ahead: Analysts expect loss amid increased regulatory scrutiny
4/30/2025 - Seeking Alpha - Healthcare
Is Moderna Stock (MRNA) a Buy Ahead of Earnings?
4/30/2025 - TipRanks Financial Blog
Price T Rowe Associates Inc. MD Sells 386,924 Shares of Moderna, Inc. (NASDAQ:MRNA)
4/30/2025 - Ticker Report
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
4/30/2025 - StockStory Articles
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for
4/29/2025 - Zacks Investment Research
Trump's FDA wants a new trial for Novavax's COVID-19 shot, sparking uncertainty about updates to other vaccines
4/29/2025 - Fortune
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics
4/29/2025 - PR Newswire
Aquatic Capital Management LLC Cuts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)
4/29/2025 - MarketBeat
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots
4/28/2025 - The Mercury News: Health
Moderna Faces Suspension After Offering UK Children 1,500 And Teddy Bears To Join COVID Trials
4/28/2025 - IB Times - Economy
Boss Class: Tracey Franklin interview
4/28/2025 - The Economist Podcast
Boss Class 3 - Recruitment: Testing, testing
4/28/2025 - The Economist Podcast
Key Events This Week: Peak Earnings Season, Canada Election, Payrolls, PCE, GDP... And Trade War Goes On
4/28/2025 - Zero Hedge
Countdown to Moderna (MRNA) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
4/28/2025 - Zacks Investment Research
HSBC Adjusts Moderna (MRNA) Price Target Amid Industry Challenges MRNA Stock News
4/28/2025 - GuruFocus
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
4/28/2025 - Zacks Investment Research
Virtus ETF Advisers LLC Buys 5,898 Shares of Moderna, Inc. (NASDAQ:MRNA)
4/28/2025 - Ticker Report
Moderna price target lowered by $9 at HSBC, here's why
4/28/2025 - The Fly
Down 36%, Is Moderna a Buy on the Dip?
4/28/2025 - Fool.com Headlines
Down 36%, Is Moderna a Buy on the Dip?
4/28/2025 - Yahoo! Finance: News
14,500 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Sassicaia Capital Advisers LLC
4/28/2025 - MarketBeat
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
3/11/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$3.24B
EBITDA (TTM)
-$3.76B
EBIT (TTM)
-$3.95B
Net Income (TTM)
-$3.56B
Balance Sheet
Total Assets (Q)
$14.14B
Total Debt (Q)
$747.00M
Total Liabilities (Q)
$3.24B
Book Value Per Share (Q)
$28.24
Cash Flow
Cash from Operations (TTM)
-$3.00B
Cash from Investing (TTM)
$1.95B
Cash from Financing (TTM)
$56.00M
Net Change in Cash (TTM)
-$999.00M
Filings
Filing Date
Friday, February 21, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
1.23
7-Day Total Return
13.57%
30-Day Total Return
-15.59%
60-Day Total Return
-21.92%
90-Day Total Return
-29.98%
Year to Date Total Return
-32.05%
1-Year Total Return
-74.13%
2-Year Total Return
-78.61%
3-Year Total Return
-79.91%
5-Year Total Return
-37.94%
52-week Low
Apr 07, 2025 - $23.15
52-week High
May 24, 2024 - $170.47
Valuation
Market Cap
$10.76B - Large Cap
Enterprise Value
$1.98B
Price/Sales (TTM)
3.31
Price/Book (Q)
0.99
Dividends and Shares
Shares Outstanding
385.00M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.modernatx.com
Phone Number
617 714 6500
Address
325 Binney Street
Cambridge, MA 02142
Country
United States
Year Founded
2010
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID... more
NASDAQ 04/30/2025 4:00PM Eastern Quotes delayed